Larimar Therapeutics GAAP EPS of -$0.41 beats by $0.07

* Larimar Therapeutics press release [https://seekingalpha.com/pr/20200727-larimar-therapeutics-reports-second-quarter-2025-financial-results] (NASDAQ:LRMR [https://seekingalpha.com/symbol/LRMR]): Q2 GAAP EPS of -$0.41 beats by $0.07.
* $203.6 million in pro forma cash, cash equivalents and marketable securities as of June 30, 2025, with projected cash runway into the fourth quarter of 2026

MORE ON LARIMAR THERAPEUTICS

* Larimar Therapeutics prices $60M stock offering [https://seekingalpha.com/news/4473984-larimar-therapeutics-prices-60m-stock-offering]
* Larimar Therapeutics drops 20% as it announces public offering [https://seekingalpha.com/news/4473759-larimar-therapeutics-drops-20-as-it-announces-public-offering]
* Seeking Alpha’s Quant Rating on Larimar Therapeutics [https://seekingalpha.com/symbol/LRMR/ratings/quant-ratings]
* Historical earnings data for Larimar Therapeutics [https://seekingalpha.com/symbol/LRMR/earnings]
* Financial information for Larimar Therapeutics [https://seekingalpha.com/symbol/LRMR/income-statement]